Primary Exploration of Cell-free DNA in the Plasma of Patients with Parathyroid Neoplasms Using Next-generation Sequencing

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2025 Mar 13

PMID 40075389

Authors

Qingyuan Zheng

Ming Cui

Ou Wang

Xiaoyan Chang

Jinheng Xiao

Tianqi Chen

Mengyi Wang

Surong Hua

Ya Hu

Quan Liao

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Plasma cell-free DNA (cfDNA) has been used to monitor gene mutations and diagnose tumors. Discriminating parathyroid carcinoma (PC) from parathyroid adenoma (PA) before surgery is difficult because of the overlap in clinical features between parathyroid neoplasms. We aimed to detect cfDNA mutations in plasma samples from PC and PA patients before surgery to predict the CDC73 status in tumor tissue and help in the differential diagnosis of parathyroid neoplasms.

Materials And Methods: Eighteen PC patients and 13 PA patients were enrolled. Plasma cfDNA was detected using next-generation sequencing, with DNA from matched peripheral white blood cells used as a control. CDC73 gene mutations were detected via whole-exome sequencing or parafibromin staining via immunohistochemistry of tumor tissues. Logistic regression was used to evaluate the ability of cfDNA mutations to predict the CDC73 status in tumor tissue and for differential diagnosis. CDC73 gene mutation or parafibromin staining loss were defined as CDC73 abnormalities.

Results: One PC patient was not tested for CDC73 abnormalities due to the absence of tumor specimen. CDC73 abnormalities were not detected in all 13 PA patients, whereas 10 PC patients harboured CDC73 abnormalities in tumor specimens (P = 0.001). Among the 10 patients, CDC73 mutations were identified in the cfDNA of 8 patients. In another 20 patients without CDC73 abnormalities in tumors, CDC73 mutation was detected in the cfDNA of 4 patients. Using the CDC73 status in cfDNA, the area under the receiver operating characteristic curve (AUC) for predicting CDC73 abnormalities in tumor tissue was 0.80 (95% CI: 0.622-0.978), and the AUC for predicting malignancy was 0.795 (95% CI 0.632-0.958).

Conclusion: This study is the first attempt to evaluate the gene mutation status of parathyroid neoplasms through the deep sequencing of plasma cfDNA, which could also help to identify PC prior to surgery.

References

Caputo V, De Falco V, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F . Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther Adv Med Oncol. 2022; 14:17588359221096878. PMC: 9082754. DOI: 10.1177/17588359221096878. View

Berger A, Schwerdel D, Costa I, Hackert T, Strobel O, Lam S . Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. Gastroenterology. 2016; 151(2):267-70. DOI: 10.1053/j.gastro.2016.04.034. View

Rutledge S, Harrison M, OConnell M, ODwyer T, Byrne M . Acute presentation of a giant intrathyroidal parathyroid adenoma: a case report. J Med Case Rep. 2016; 10(1):286. PMC: 5070099. DOI: 10.1186/s13256-016-1078-1. View

Oxnard G, Paweletz C, Kuang Y, Mach S, OConnell A, Messineo M . Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20(6):1698-1705. PMC: 3959249. DOI: 10.1158/1078-0432.CCR-13-2482. View

Shaha A, Shah J . Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999; 86(3):378-80. View

Hu Y, Zhang X, Wang O, Bi Y, Xing X, Cui M . The genomic profile of parathyroid carcinoma based on whole-genome sequencing. Int J Cancer. 2020; 147(9):2446-2457. DOI: 10.1002/ijc.33166. View

Wan J, Massie C, Garcia-Corbacho J, Mouliere F, Brenton J, Caldas C . Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017; 17(4):223-238. DOI: 10.1038/nrc.2017.7. View

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R . VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016; 44(11):e108. PMC: 4914105. DOI: 10.1093/nar/gkw227. View

Thorvaldsdottir H, Robinson J, Mesirov J . Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2012; 14(2):178-92. PMC: 3603213. DOI: 10.1093/bib/bbs017. View

10.

Kammenga J . The background puzzle: how identical mutations in the same gene lead to different disease symptoms. FEBS J. 2017; 284(20):3362-3373. DOI: 10.1111/febs.14080. View

11.

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C . Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017; 117(7):1017-1025. PMC: 5625666. DOI: 10.1038/bjc.2017.250. View

12.

Walker M, Silverberg S . Primary hyperparathyroidism. Nat Rev Endocrinol. 2017; 14(2):115-125. PMC: 6037987. DOI: 10.1038/nrendo.2017.104. View

13.

Hobbs M, Pole A, Pidwirny G, Rosen I, Zarbo R, Coon H . Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet. 1999; 64(2):518-25. PMC: 1377760. DOI: 10.1086/302259. View

14.

Cavalier E, Betea D, Schleck M, Gadisseur R, Vroonen L, Delanaye P . The third/second generation PTH assay ratio as a marker for parathyroid carcinoma: evaluation using an automated platform. J Clin Endocrinol Metab. 2014; 99(3):E453-7. DOI: 10.1210/jc.2013-3730. View

15.

Hu Y, Zhang X, Wang O, Xing X, Cui M, Wang M . Spectrum of mitochondrial genomic variation in parathyroid neoplasms. Endocrine. 2021; 74(3):690-697. DOI: 10.1007/s12020-021-02825-8. View

16.

Siljan W, Holter J, Nymo S, Schjalm C, Muller F, Jenum P . Circulating cell-free DNA is elevated in community-acquired bacterial pneumonia and predicts short-term outcome. J Infect. 2016; 73(4):383-6. DOI: 10.1016/j.jinf.2016.07.011. View

17.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

18.

Hu Y, Bi Y, Cui M, Zhang X, Su Z, Wang M . THE INFLUENCE OF SURGICAL EXTENT AND PARAFIBROMIN STAINING ON THE OUTCOME OF PARATHYROID CARCINOMA: 20-YEAR EXPERIENCE FROM A SINGLE INSTITUTE. Endocr Pract. 2019; 25(7):634-641. DOI: 10.4158/EP-2018-0538. View

19.

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

20.

Schantz A, Castleman B . Parathyroid carcinoma. A study of 70 cases. Cancer. 1973; 31(3):600-5. DOI: 10.1002/1097-0142(197303)31:3<600::aid-cncr2820310316>3.0.co;2-0. View